For the roughly one million Americans living with multiple sclerosis, treatment choice often hinges not just on efficacy but on cost and access. The absence of direct comparative data between two leading anti-CD20 therapies has left clinicians and patients navigating that choice without solid evidence — until now.

This phase 3, multicenter, double-blind noninferiority trial enrolled 216 adults with newly diagnosed relapsing MS and recent disease activity, randomizing them 3:2 to receive either rituximab or ocrelizumab every six months over a 24-month period. The primary endpoint — freedom from new or enlarging T2-weighted MRI lesions between months 6 and 24 — was achieved in 92.2% of rituximab recipients versus 94.8% of ocrelizumab recipients. The risk difference of -2.6 percentage points (95% CI: -9.4 to 4.3) cleared the predefined noninferiority margin of -10 percentage points. Relapse rates, disability trajectories, and cognitive performance profiles tracked closely between groups. Notably, infections were modestly more frequent in the rituximab arm (82% versus 69%), a signal worth monitoring.

This finding carries substantial real-world weight. Ocrelizumab (Ocrevus) is FDA-approved specifically for MS and carries a price tag frequently exceeding $65,000 annually in the United States. Rituximab, an older biosimilar-accessible agent, can cost a fraction of that. Both drugs deplete B-cells via CD20 targeting, but rituximab's chimeric structure and different infusion schedules have historically drawn regulatory and payer scrutiny. The trial's 216-participant size is modest, and the 24-month window may not capture long-term divergence in safety profiles — particularly regarding infection risk and hypogammaglobulinemia. Still, for newly diagnosed patients in health systems where cost determines access, this represents potentially paradigm-shifting evidence. The infection differential, though not severe in this cohort, warrants longer follow-up given that cumulative immunosuppression risks compound over years of MS management. Overall, this is a clinically meaningful finding that should accelerate formulary and prescribing conversations globally.